As of 1 January 2027, Novo Nordisk will lower the list price, or wholesale acquisition cost, to $675 for Wegovy (semaglutide) injection 2.4mg and tablets 25mg, Ozempic (semaglutide) injection 0.5mg, 1mg and 2mg, and Rybelsus (semaglutide) tablets 7mg or 14mg.
This equates to a reduction of approximately 50% for Wegovy and 35% for Ozempic, compared to their current list price, and applies to all doses of these medicines.
The announcement is part of the company’s commitment to improving affordability for US patients.
Jamey Millar, executive vice president, US Operations at Novo Nordisk, said: “Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States.
“Private and public payers, as well as patients, want access and have been calling for lower list prices. [This] answers that call and removes cost barriers so the value of Wegovy and Ozempic can be realized by more patients.
“The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs.”
Not all GLP-1s are the same. Semaglutide is the active ingredient in Wegovy and Ozempic, offering powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with indications for adults with obesity (Wegovy), type 2 diabetes (Ozempic), type 2 diabetes and chronic kidney disease (Ozempic injection), and comorbid cardiovascular disease (Wegovy and Ozempic).
This is the latest in a series of efforts from Novo Nordisk to make it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy and Ozempic in the way that best fits their lives. This change does not impact other access efforts, including direct-to-patient, self-pay prices.